LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients
about
Novel Molecular Markers for Breast CancerTargeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer TypeMetformin as a new anti-cancer drug in adrenocortical carcinomaToo much cleavage of cyclin E promotes breast tumorigenesis.Components of the canonical and non-canonical Wnt pathways are not mis-expressed in pituitary tumorsTanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway.Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner.Mesenchymal and stem-like cell properties targeted in suppression of chronically-induced breast cell carcinogenesisCyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells.Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast CancerHbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.Pathogenesis and heterogeneity of ovarian cancer.Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cellsCytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.
P2860
Q26753160-1D3D3A05-595D-42CC-BF1D-3A4F98CFDFB7Q28066522-00DF5C29-AE22-4409-93CC-CEACF118FA88Q28468634-8E05EFBF-AC3B-4978-8224-B619C1EAAA5FQ34221065-1658A44B-2C2E-4537-B8DC-6C66A351EE59Q34701446-698E3F56-FDDA-4B3A-B7A1-DDEAAA5D74A3Q35058837-220F1D1B-3E3B-4621-B1C4-D1F8EC51F8B0Q35079179-988A002E-17A9-43EF-8B60-049BB4578BBCQ35897417-B50777D8-0DB9-461E-BF55-9D19AE90597EQ36288515-017E358B-7F80-4450-A2E5-26930D061CFBQ36464991-1C246229-2B2D-44A4-BB00-8433BD7160FEQ36772254-CCCC175D-7864-4AC7-B3B9-0EDBB1809DC3Q36918276-3ACD4982-FB01-4023-AF7E-940BA428C40AQ37057171-85E34A1A-5591-44CD-A99D-BB2B104F18F9Q37172133-CE3657A3-9919-4890-902D-0CE89EAEE10DQ37546692-DAD54D5B-9ED8-4286-AF37-FD69CFCB06B7Q37716464-88D976F2-53A9-4681-8E38-8E13E899480FQ38743594-7A98ACE0-E7AE-488D-A2E7-7AEB3E2067D7Q41874772-96AB680B-3B97-484B-A37C-C7F13DA43A39Q49558301-508DDFAC-F517-40E7-B0C4-21790DA554C6Q52955581-049A0FA0-4F8B-477C-A857-163D25218446
P2860
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients
@ast
LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients
@en
LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients
@nl
type
label
LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients
@ast
LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients
@en
LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients
@nl
prefLabel
LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients
@ast
LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients
@en
LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients
@nl
P2093
P2860
P1433
P1476
LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients
@en
P2093
Caimiao Wei
Gordon B Mills
Hannah F Wingate
Kelly K Hunt
Khandan Keyomarsi
MyLinh T Duong
Wenbin Liu
P2860
P304
P356
10.1371/JOURNAL.PGEN.1002538
P577
2012-03-29T00:00:00Z